KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Receivables: 2018-2025

Historic Receivables for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $49.5 million.

  • Castle Biosciences' Receivables fell 1.55% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 18.12%. This contributed to the annual value of $51.2 million for FY2024, which is 33.72% up from last year.
  • Per Castle Biosciences' latest filing, its Receivables stood at $49.5 million for Q3 2025, which was down 5.41% from $52.3 million recorded in Q2 2025.
  • Castle Biosciences' Receivables' 5-year high stood at $56.4 million during Q1 2025, with a 5-year trough of $14.3 million in Q1 2021.
  • For the 3-year period, Castle Biosciences' Receivables averaged around $43.9 million, with its median value being $46.0 million (2024).
  • As far as peak fluctuations go, Castle Biosciences' Receivables fell by 2.11% in 2021, and later spiked by 63.15% in 2023.
  • Quarterly analysis of 5 years shows Castle Biosciences' Receivables stood at $17.3 million in 2021, then surged by 35.84% to $23.5 million in 2022, then spiked by 63.15% to $38.3 million in 2023, then surged by 33.72% to $51.2 million in 2024, then declined by 1.55% to $49.5 million in 2025.
  • Its Receivables was $49.5 million in Q3 2025, compared to $52.3 million in Q2 2025 and $56.4 million in Q1 2025.